(vianews) - shares of gensight biologics (cac 40: sight.pa) jumped by a staggering 18.18% to €0.91 at 15:02 est on friday, following the last session's upward trend. cac 40 is rising 1.14% to €7,373.72, following the last session's downward trend. this seems, up until now, an all-around up trend exchanging session today.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. the company was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.59.
volume
today's last reported volume for gensight biologics is 537085 which is 26.23% above its average volume of 425458.
more news about gensight biologics (sight.pa).